Patents by Inventor John Foerster

John Foerster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION THEREOF
    Publication number: 20240093159
    Abstract: The present invention relates to virus-like particles (VLPs) having a high affinity protein attachment system which allows interchangeable decoration with any functional molecule of choice. The present invention further relates to processes of producing the VLPs, including a rapid single cell process, and uses of the VLPs in research, diagnosis and as vaccines for use in prevention/treatment of diseases.
    Type: Application
    Filed: November 26, 2021
    Publication date: March 21, 2024
    Inventor: John FOERSTER
  • Methods concerning PPAR delta and antagonists thereof
    Patent number: 9155289
    Abstract: Non-human animals which overexpress PPARd or which express transgenic PPARd are useful as models for inflammatory skin conditions such as psoriasis. Test substances can be screened to assess their suitability for the treatment of inflammatory skin conditions such as psoriasis. Methyl 3-({[2-(methoxy)-4-phenyl]amino}sulfonyl)-2-thiophenecarboxylate can be administered topically for the prevention or treatment of psoriasis.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: October 13, 2015
    Assignee: University Court of the University of Dundee
    Inventors: Colin Palmer, John Foerster, Nainamalai Sitherswaran
  • Identification of Therapeutic Targets in Cutaneous SCC
    Publication number: 20130336987
    Abstract: The present invention discloses a series of genes and/or proteins associated with cutaneous squamous cell carcinoma (cSCC) and provides polynucleotides and/or polypeptides for use in the treatment and/or prevention of cSCC. The invention further relates to methods of diagnosing cSCC and provides oligonucleotides/polypeptide probes and primers.
    Type: Application
    Filed: October 7, 2011
    Publication date: December 19, 2013
    Applicant: UNIVERSITY OF DUNDEE
    Inventors: Andrew South, Celine Pourreyron, Stephen Watt, John Foerster
  • Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated PP2Ac
    Patent number: 8202696
    Abstract: The present invention relates to a method of preventing or treating a disease correlated with or caused by non-physiologically increased intracellular levels of the catalytic subunit of microtubule-associated protein phosphatase 2A (PP2Ac) comprising administering to a subject affected by said disease or in danger of developing said disease a pharmaceutically effective amount of a protein selected from the group of MID1 or MID2 or a nucleic acid encoding said protein.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: June 19, 2012
    Assignee: Max-Planck-Gessellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Susann Schweiger, Hans-Hilger Ropers, Jennifer Winter, Sybille Krauss, Vanessa Suckow, Rainer Schneider, Alexander Trockenbacher, John Foerster
  • METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF
    Publication number: 20110263691
    Abstract: Non-human animals which overexpress PPARd or which express transgenic PPARd are useful as models for inflammatory skin conditions such as psoriasis. Test substances can be screened to assess their suitability for the treatment of inflammatory skin conditions such as psoriasis. Methyl 3-({[2-(methoxy)-4-phenyl]amino}sulfonyl)-2-thiophenecarboxylate can be administered topically for the prevention or treatment of psoriasis.
    Type: Application
    Filed: July 31, 2009
    Publication date: October 27, 2011
    Inventors: Colin Palmer, John Foerster, Nainamalai Sitheswaran
  • Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
    Publication number: 20070134654
    Abstract: The present invention relates to a method of preventing or treating a disease correlated with or caused by non-physiologically increased intracellular levels of the catalytic subunit of microtubule-associated protein phosphatase 2A (PP2Ac) comprising administering to a subject affected by said disease or in danger of developing said disease a pharmaceutically effective amount of a protein selected from the group of MID1 or MID2 or a nucleic acid encoding said protein.
    Type: Application
    Filed: May 15, 2003
    Publication date: June 14, 2007
    Applicant: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Susann Schweiger, Hans-Hilger Ropers, Jennifer Winter, Sybille Krauss, Vanessa Suckow, Rainer Schneider, Alexander Trockenbacher, Lars Klimaschewski, John Foerster, Sebastian Haesler